Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SITC 2024 | Boosting antitumor activity with oncolytic viruses prior to ICI immunotherapy

Roger Li • 7 Nov 2024
SITC 2024
Bladder Cancer Genitourinary Cancer Checkpoint Inhibitors

Roger Li, MD, H. Lee Moffitt Cancer Center, Tampa, FL, provides a brief overview on the joint mechanism of action for oncolytic viruses and immune checkpoint inhibitors (ICIs) to induce tumor cell death. Oncolytic viruses release cancer neoantigens to activate the innate immune system and ICIs reinvigorate the T-cells to boost antitumor activity. This interview took place at the 39th Annual Meeting SITC 2024 at Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Roger Li

Advancements and recent approvals in NMIBC: SunRISe-1, KEYNOTE-057, and more
1:07
Advancements and recent approvals in NMIBC: SunRISe-1, KEYNOTE-057, and more
Roger Li • 13 Feb 2025
Plasma ctDNA as a staging tool in upper tract urothelial carcinoma
2:45
Plasma ctDNA as a staging tool in upper tract urothelial carcinoma
Roger Li • 13 Feb 2025
The case for local therapies alone in BCG-unresponsive NMBIC
1:23
The case for local therapies alone in BCG-unresponsive NMBIC
Roger Li • 13 Feb 2025
Oncolytic virus therapy in early-stage bladder cancer w/ direct lesion contact via intravesical use
1:44
Oncolytic virus therapy in early-stage bladder cancer w/ direct lesion contact via intravesical use
Roger Li • 7 Nov 2024

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026
The content of VJOncology is intended for healthcare professionals